Meridian Bioscience said this week that it has received medical device license approval from Health Canada to market its Illumigene Mycoplasma and Pertussis assays.

The Illumigene Mycoplasma test amplifies specific DNA from Mycoplasma pneumonia to detect the bacterium and help patients receive appropriate treatment in a timely manner. Meantime, Illumigene Pertussis amplifies a specific DNA target to detect Bordetella pertussis from nasopharyngeal swabs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.